Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA7 | P43166 | 5/20 | 0.42 |
| ▸ | CA9 | Q16790 | 5/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TYR | P14679 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28347412 | 0.80 | ALDH1A1 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16280538 | 0.76 | ADRA2A (0.38) | CA12CA1CA2CA9CA14 | |
| SCHEMBL15360275 | 0.76 | CA9 (0.44) | CA12CA1CA2CA9CA14 | |
| SCHEMBL18884380 | 0.76 | HSD17B10 (0.52) | ALDH1A1ALOX15CYP2C9HSD17B10LMNA | |
| SCHEMBL18884370 | 0.76 | TRPA1 (0.52) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL16284442 | 0.76 | MAPT (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5795933 | 0.75 | IDO1 (0.45) | MAOBCA12CA1CA2CA7 | |
| SCHEMBL30963343 | 0.75 | IDO1 (0.45) | MAOBCA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL16280031 | 0.75 | MAPT (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17264177 | 0.75 | MAOB (0.48) | MAOBCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158351-A1 | S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS | XAVIER UNIVERSITY OF LOUISIANA | 2024-05-16 | — | — | US | disclosed |
| US-11912660-B2 | S6K1 protein kinase inhibitors as cancer therapeutics | XAVIER UNIVERSITY OF LOUISIANA (US) | 2024-02-27 | — | — | US | disclosed |
| US-20210323919-A1 | S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS | XAVIER UNIVERSITY OF LOUISIANA | 2021-10-21 | — | — | US | disclosed |
| CN-110709460-A | Rubber composition for tire and tire | 株式会社普利司通 | 2020-01-17 | — | — | CN | disclosed |
| US-7074959-B2 | Methods and systems for remediating hydrazine-contaminated equipment and/or surfaces | NEW MEXICO HIGHLANDS UNIVERSITY (US) | 2006-07-11 | — | — | US | disclosed |
| US-6955706-B2 | Liquid degassing system for power plant system layup | DOMINION ENGINEERING INC (US) | 2005-10-18 | — | — | US | disclosed |
| US-20040025696-A1 | Liquid degassing system for power plant system layup | BANK OF AMERICA, N.A., AS COLLATERAL AGENT | 2004-02-12 | — | — | US | disclosed |
| US-20040024251-A1 | Methods and systems for hydrazine remediation | HELVENSTON MERRITT C (US) | 2004-02-05 | — | — | US | disclosed |
| WO-2003086573-A1 | LIQUID DEGASSING SYSTEM FOR POWER PLANT SYSTEM LAYUP | DOMINION ENGINEERING, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323919-A1 | S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS | RPS6KA6, RPS6KA1, RPS6KA3 | MAOB 4720/4885CA12 4718/4885CA1 4839/4885 |
| US-11912660-B2 | S6K1 protein kinase inhibitors as cancer therapeutics | RPS6KA6, RPS6KA1, RPS6KA3 | MAOB 4720/4885CA12 4718/4885CA1 4839/4885 |
| US-20240158351-A1 | S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS | RPS6KA6, RPS6KA1, RPS6KA3 | MAOB 4720/4885CA12 4718/4885CA1 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.